JO3376B1 - خليط متحد مضاد للفيروسات المسببة للاورام - Google Patents

خليط متحد مضاد للفيروسات المسببة للاورام

Info

Publication number
JO3376B1
JO3376B1 JOP/2012/0207A JOP20120207A JO3376B1 JO 3376 B1 JO3376 B1 JO 3376B1 JO P20120207 A JOP20120207 A JO P20120207A JO 3376 B1 JO3376 B1 JO 3376B1
Authority
JO
Jordan
Prior art keywords
retroviral combination
retroviral
combination
darunavir
ritonavir
Prior art date
Application number
JOP/2012/0207A
Other languages
English (en)
Inventor
Lulla Amar
Malhotra Geena
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3376(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of JO3376B1 publication Critical patent/JO3376B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

توجد هناك مركبات صيدلانية من ريتونافير ودارونافير كما توجد هناك طرق لانتاجه.
JOP/2012/0207A 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام JO3376B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
JO3376B1 true JO3376B1 (ar) 2019-03-13

Family

ID=54289250

Family Applications (2)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام
JOP/2012/0207A JO3376B1 (ar) 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام

Country Status (19)

Country Link
US (1) US9339470B2 (ar)
EP (2) EP2505193B1 (ar)
JP (2) JP2011507940A (ar)
CN (2) CN101925350B (ar)
AP (2) AP2013007064A0 (ar)
AT (1) ATE555778T1 (ar)
AU (1) AU2008339633A1 (ar)
BR (1) BRPI0819534A2 (ar)
CA (1) CA2710605C (ar)
DK (1) DK2242482T3 (ar)
ES (2) ES2385819T3 (ar)
GT (1) GT200800303A (ar)
JO (2) JO2814B1 (ar)
MX (1) MX2010007083A (ar)
PA (1) PA8809601A1 (ar)
PE (2) PE20140926A1 (ar)
RU (2) RU2531089C2 (ar)
WO (1) WO2009081174A2 (ar)
ZA (1) ZA201004505B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
PL2729130T3 (pl) * 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
CN103841962B (zh) * 2011-07-07 2016-08-17 爱尔兰詹森科学公司 地瑞纳韦配制品
CN104411300A (zh) * 2012-05-03 2015-03-11 希普拉有限公司 抗逆转录病毒组合物
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨,替诺福韦,达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US11045423B2 (en) * 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技(杭州)有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
AU641375B2 (en) 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
WO1990007199A1 (en) 1988-12-20 1990-06-28 Mawzones Developments Limited Focussing device for a microwave antenna
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PL1765337T3 (pl) * 2004-07-08 2009-02-27 Tibotec Pharm Ltd Połączenie tenofowiru, ritonawiru i TMC114
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ATE474560T1 (de) 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral

Also Published As

Publication number Publication date
ZA201004505B (en) 2013-05-29
WO2009081174A2 (en) 2009-07-02
AP2013007064A0 (en) 2013-08-31
WO2009081174A3 (en) 2009-08-27
JO2814B1 (ar) 2014-09-15
AU2008339633A1 (en) 2009-07-02
CN101925350B (zh) 2014-04-30
PE20140926A1 (es) 2014-08-06
RU2014111723A (ru) 2015-10-10
HK1149905A1 (en) 2011-10-21
CN103638032A (zh) 2014-03-19
RU2531089C2 (ru) 2014-10-20
CN101925350A (zh) 2010-12-22
RU2010131006A (ru) 2012-02-10
AP2855A (en) 2014-02-28
BRPI0819534A2 (pt) 2015-05-26
GT200800303A (es) 2009-09-18
EP2505193B1 (en) 2018-05-02
JP2011507940A (ja) 2011-03-10
US9339470B2 (en) 2016-05-17
ES2674730T3 (es) 2018-07-03
PE20091530A1 (es) 2009-09-25
PA8809601A1 (es) 2009-07-23
CA2710605A1 (en) 2009-07-02
AP2010005325A0 (en) 2010-08-31
ES2385819T3 (es) 2012-08-01
EP2505193A1 (en) 2012-10-03
EP2242482A2 (en) 2010-10-27
DK2242482T3 (da) 2012-08-06
JP2015007071A (ja) 2015-01-15
RU2675831C2 (ru) 2018-12-25
EP2242482B1 (en) 2012-05-02
MX2010007083A (es) 2010-10-20
CA2710605C (en) 2017-05-02
ATE555778T1 (de) 2012-05-15
US20110008429A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
IL262205A (en) Protein formulations and methods for their preparation
ZA200902803B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2002263A4 (en) Cancer Immune Compositions and Methods of Use
PL3100728T3 (pl) Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
SG2013054218A (en) Powdered protein compositions and methods of making same
ZA201208265B (en) Pharmaceutical compositions and methods of making same
ZA200900347B (en) Preparation of pharmaceutical compositions
EP2254555A4 (en) APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
ZA201008379B (en) Glucocorticoid mimetics,methods of making them,pharmaceutical compositions,and uses thereof
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
EP2254420A4 (en) CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
JO2814B1 (ar) خليط متحد مضاد للفيروسات المسببة للأورام
IL220513A0 (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
TN2009000510A1 (en) Extended release formulation of nevirapine
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.
IL219018A (en) Radzolid Pharmaceuticals and Uses
MX2013005699A (es) Composiciones de interferon-beta estables conservadas.
TN2009000044A1 (en) Crystal form of epothilone b and use in pharmaceutical compositions
WO2010127264A3 (en) HNF4α ANTAGONISTS AND METHODS OF USE
IL198446A0 (en) Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
HK1141445A (en) Lyophilized pharmaceutical compositions and methods of making and using same
IL195845A0 (en) Methods of making and using rubidium-81-containing compositions